ClinicalTrials.gg
Not yet recruitingNCT07278817Updated Nov 5, 2026

Monitoring and Rehabilitation for ICIACI Rehabilitation:A Cohort Study

An observational study in Immune Checkpoint Inhibitor-Related Myocarditis, sponsored by China-Japan Friendship Hospital. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by China-Japan Friendship Hospital · Observational

How we know

Updated Nov 5, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
340
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Immune checkpoint inhibitor-associated cardiac injury (ICIACI) is a low-incidence but highly fatal adverse event. A significant knowledge gap exists regarding the disease characteristics and recovery status of patients during the ICIACI convalescent phase. The objectives of this study are to establish a national, multicenter cohort for this patient population and to comprehensively describe their clinical profiles from an integrated Traditional Chinese and Western medicine standpoint, as well as their current rehabilitation status.

Read the detailed description

The cohort study consists of a retrospective and a prospective cohort, enrolling eligible rehabilitation ICIACI patients from multiple centers across China. The retrospective cohort records baseline assessment data from electronic medical records and clinical sources, including demographics, cancer diagnosis and immunotherapy details, laboratory tests, electrocardiograms, imaging studies, quality of life and exercise tolerance assessments, TCM syndrome scores, and rehabilitation information, to define TCM and Western medicine clinical characteristics and rehabilitation status. The prospective cohort patients are followed up at 2, 4, and 12 weeks after enrollment, with MACE as the primary endpoint and quality of life scores as the secondary endpoint, to evaluate influencing factors of rehabilitation and its impact on prognosis.

02

Conditions studied

  • Immune Checkpoint Inhibitor-Related Myocarditis

Browse trials for

03

In context

Myocarditis

175 studies on the registry are indexed under Myocarditis; 75 are open to participants now.

This study's planned enrollment of 340 is above the median of 200 across 121 observational studies indexed under Myocarditis.

Browse Myocarditis studies →

Lead sponsor

China-Japan Friendship Hospital is the lead sponsor of 179 studies on the registry; 112 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Under the established protocol, patients presenting with ICIACI will be enrolled from the China-Japan Friendship Hospital, Fuwai Hospital of the Chinese Academy of Medical Sciences, the Second Affiliated Hospital of Nanchang University, and Weifang Hospital of Traditional Chinese Medicine during the period from December 2025 to July 2028.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 to 80 years, inclusive
  • confirmed by cytology or histopathology
  • Diagnosis of ICIACI following ICI therapy
  • Assessed by the Multidisciplinary Team for Immune-Related Adverse Events as clinically recovered and entering the rehabilitation.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of fulminant myocarditis or cardiac function of IV
  • Clear evidence suggesting cardiac injury not attributable to ICIs
  • Concurrent acute cardiovascular events or malignant arrhythmias
  • Coexisting severe immune-related adverse events affecting other organ systems
  • Associated severe systemic diseases, such as severe hepatic or renal insufficiency, or severe infection.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
340 participants (estimated)
Patient registry
No

Groups and cohorts

  • ICIACI-Rehab Cohort

    This observational cohort includes patients with immune checkpoint inhibitor-associated cardiac injury (ICIACI). Clinical characteristics, cardiac function, rehabilitation status, and clinical outcomes are assessed during follow-up. Rehabilitation and other treatments are provided according to routine clinical practice, without interventions assigned by the study protocol.

06

What researchers measure

Primary outcomes

  1. MACE

    Cardiovascular Death, Cardiac Arrest, Cardiogenic Shock, High-Grade Atrioventricular Block

    Time frame: 2, 4, and 12 weeks after enrollment

Secondary outcomes

  1. Change in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Health Utility Index

    The EQ-5D-5L assesses health-related quality of life across five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Responses are converted into a health utility index using the Chinese EQ-5D-5L value set, with scores ranging from -0.391 to 1.000. Higher scores indicate better health-related quality of life. Changes from baseline to Weeks 2, 4, and 12 will be assessed.

    Time frame: 2, 4, and 12 weeks after enrollment

  2. Change in EuroQol Visual Analogue Scale (EQ VAS) Score

    The EuroQol Visual Analogue Scale (EQ VAS) assesses participants' self-rated overall health status on a scale ranging from 0 (worst imaginable health) to 100 (best imaginable health). Higher scores indicate better self-rated health. Changes from baseline to Weeks 2, 4, and 12 will be assessed.

    Time frame: 2, 4, and 12 weeks after enrollment

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jul 2028, 19 months later.

Of 70 non-industry observational studies under Myocarditis, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 251. This study's planned 19 months is below that.

Counting every sponsor, half of 72 studies reached it within 69 months; a quarter within 22 and three quarters within 251.

Start moved once since we started tracking on Sep 25, 2026: Dec 2025 → Dec 2026, on Nov 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2025
First posted
Dec 12, 2025
StartEst.
Dec 30, 2026was Dec 2025
Primary completionEst.
Jul 31, 2028
CompletionEst.
Jul 31, 2028
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Dec 30, 2025→Dec 30, 2026
Nov 5, 2026
Secondary outcomes
2 added, 1 removed
What changed in the outcomes
  • AddedChange in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Health Utility IndexTime frame: 2, 4, and 12 weeks after enrollment
  • AddedChange in EuroQol Visual Analogue Scale (EQ VAS) ScoreTime frame: 2, 4, and 12 weeks after enrollment
  • RemovedEQ-5DTime frame: 2, 4, and 12 weeks after enrollment
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Start date Dec 30, 2025→Dec 30, 2026
    Secondary outcomes 2 added, 1 removed
    What changed in the outcomes
    • AddedChange in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Health Utility IndexTime frame: 2, 4, and 12 weeks after enrollment
    • AddedChange in EuroQol Visual Analogue Scale (EQ VAS) ScoreTime frame: 2, 4, and 12 weeks after enrollment
    • RemovedEQ-5DTime frame: 2, 4, and 12 weeks after enrollment
    + 2 other changes: verification date and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07278817
Collaborators
Weifang Hospital of Traditional Chinese Medicine, Chinese Academy of Medical Sciences, Fuwai Hospital, Second Affiliated Hospital of Nanchang University
Responsible party
Jingyi Ren (Professor of medicine(Cardiology), Deputy Director of the Cardiology Department and Director of the Heart Failure Center, China-Japan Friendship Hospital) — Principal investigator
First posted
Dec 12, 2025
Start date
Dec 30, 2026 (estimated)
Primary completion
Jul 31, 2028 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Nov 5, 2026

Study contacts

Chengcheng Li, Dr
Contact
lcc77983@126.com
010-84206809
Jingyi Ren, Professor
principal investigator · China-Japan Friendship Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion